{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:15:07Z","timestamp":1789456507235,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04157-w","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:36:49Z","timestamp":1786513009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of pharmacological therapies in non-obstructive hypertrophic cardiomyopathy: a frequentist network meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9887-2434","authenticated-orcid":false,"given":"Bharath","family":"Kumar G","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumitha","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi S","family":"Ibrahimpur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richardson","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash Ranjan","family":"Meher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"9","key":"4157_CR1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ejhf.541","volume":"18","author":"E Ammirati","year":"2016","unstructured":"Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I (2016) Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail 18(9):1106\u20131118","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"4157_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jchf.2018.02.010","volume":"6","author":"JB Geske","year":"2018","unstructured":"Geske JB, Ommen SR, Gersh BJ (2018) Hypertrophic Cardiomyopathy: Clinical Update. JACC Heart Fail 6(5):364\u2013375","journal-title":"JACC Heart Fail"},{"key":"4157_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pcad.2023.08.006","volume":"80","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wang A (2023) Medical therapies for hypertrophic cardiomyopathy: Current state of the art. Prog Cardiovasc Dis 80:32\u201337","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"4157_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ejhf.1715","volume":"22","author":"CV Tuohy","year":"2020","unstructured":"Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB (2020) Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail 22(2):228\u2013240","journal-title":"Eur J Heart Fail"},{"key":"4157_CR5","doi-asserted-by":"publisher","first-page":"1477487","DOI":"10.3389\/fcvm.2024.1477487","volume":"11","author":"A Abunada","year":"2025","unstructured":"Abunada A, Shah M, Kumar A et al (2025) Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials. Front Cardiovasc Med 11:1477487 Published 2025 Jan 15","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"4157_CR6","doi-asserted-by":"publisher","first-page":"102658","DOI":"10.1016\/j.jchf.2025.102658","volume":"13","author":"MY Desai","year":"2025","unstructured":"Desai MY, Maurizi N, Biagini E et al (2025) Pathophysiology and therapeutic needs in nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail 13(11):102658","journal-title":"JACC Heart Fail"},{"issue":"6","key":"4157_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10741-025-10535-w","volume":"30","author":"L Ordine","year":"2025","unstructured":"Ordine L, Polizzi R, Canciello G et al (2025) Unveiling the complexity of nonobstructive hypertrophic cardiomyopathy. Heart Fail Rev 30(6):1141\u20131153","journal-title":"Heart Fail Rev"},{"key":"4157_CR8","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.amjcard.2023.10.074","volume":"212S","author":"E Hutt","year":"2024","unstructured":"Hutt E, Desai MY (2024) Medical treatment strategies for hypertrophic cardiomyopathy. Am J Cardiol 212S:S33\u2013S41","journal-title":"Am J Cardiol"},{"issue":"1","key":"4157_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s44348-025-00050-9","volume":"33","author":"KA Kim","year":"2025","unstructured":"Kim KA, Jung MH (2025) Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy. J Cardiovasc Imaging 33(1):13 Published 2025 Sep 24","journal-title":"J Cardiovasc Imaging"},{"issue":"1","key":"4157_CR10","doi-asserted-by":"publisher","first-page":"e24207","DOI":"10.1002\/clc.24207","volume":"47","author":"MA Sawan","year":"2024","unstructured":"Sawan MA, Prabakaran S, D\u2019Souza M et al (2024) A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy. Clin Cardiol 47(1):e24207","journal-title":"Clin Cardiol"},{"issue":"4","key":"4157_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA et al (2022) Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 79(4):390\u2013414","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"4157_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11897-021-00523-0","volume":"18","author":"M Zampieri","year":"2021","unstructured":"Zampieri M, Berteotti M, Ferrantini C et al (2021) Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives. Curr Heart Fail Rep 18(4):169\u2013179","journal-title":"Curr Heart Fail Rep"},{"issue":"17","key":"4157_CR13","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.3390\/jcm12175710","volume":"12","author":"A Ottaviani","year":"2023","unstructured":"Ottaviani A, Mansour D, Molinari LV et al (2023) Revisiting diagnosis and treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. J Clin Med 12(17):5710 Published 2023 Sep 1","journal-title":"J Clin Med"},{"key":"4157_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijcard.2017.06.071","volume":"243","author":"F Pelliccia","year":"2017","unstructured":"Pelliccia F, Pasceri V, Limongelli G et al (2017) Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol 243:379\u2013384","journal-title":"Int J Cardiol"},{"issue":"12","key":"4157_CR15","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.3390\/jcm14124228","volume":"14","author":"M Alfarano","year":"2025","unstructured":"Alfarano M, Ciccarelli F, Marchionni G et al (2025) Hypertrophic cardiomyopathy and phenocopies: new therapies for old diseases-current evidence and future perspectives. J Clin Med 14(12):4228 Published 2025 Jun 13","journal-title":"J Clin Med"},{"key":"4157_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.amjcard.2024.07.007","volume":"226","author":"E Shang","year":"2024","unstructured":"Shang E, Tan H (2024) Comparison of drug therapy efficacy in patients with hypertrophic cardiomyopathy: a network meta-analysis. Am J Cardiol 226:97\u2013107","journal-title":"Am J Cardiol"},{"issue":"6","key":"4157_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.medcli.2016.02.025","volume":"147","author":"B Hutton","year":"2016","unstructured":"Hutton B, Catal\u00e1-L\u00f3pez F, Moher D (2016) PRISMA-NMA [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA]. Med Clin (Barc) 147(6):262\u2013266","journal-title":"Med Clin (Barc)"},{"key":"4157_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"18, Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"4157_CR19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"19, Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res 27(6):1785\u20131805","journal-title":"Stat Methods Med Res"},{"key":"4157_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898 Published 2019 Aug 28","journal-title":"BMJ"},{"issue":"4","key":"4157_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394","journal-title":"J Clin Epidemiol"},{"issue":"21","key":"4157_CR22","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG et al (2020) Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 75(21):2649\u20132660","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"4157_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJMoa2505927","volume":"393","author":"MY Desai","year":"2025","unstructured":"Desai MY, Owens AT, Abraham T et al (2025) Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. N Engl J Med 393(10):961\u2013972","journal-title":"N Engl J Med"},{"issue":"21","key":"4157_CR24","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","volume":"83","author":"MS Maron","year":"2024","unstructured":"Maron MS, Mahmod M, Abd Samat AH et al (2024) Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 83(21):2037\u20132048","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"4157_CR25","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.jchf.2025.01.021","volume":"13","author":"S Papapostolou","year":"2025","unstructured":"Papapostolou S, Iles L, O\u2019Brien J et al (2025) The antifibrotic effects of eplerenone in hypertrophic cardiomyopathy: a randomized clinical trial. JACC Heart Fail 13(7):102415","journal-title":"JACC Heart Fail"},{"issue":"3","key":"4157_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","volume":"4","author":"CJ Coats","year":"2019","unstructured":"Coats CJ, Pavlou M, Watkinson OT et al (2019) Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol 4(3):230\u2013235","journal-title":"JAMA Cardiol"},{"issue":"6","key":"4157_CR27","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ejhf.3291","volume":"26","author":"L Velicki","year":"2024","unstructured":"Velicki L, Popovic D, Okwose NC et al (2024) Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: an open label randomized controlled trial (SILICOFCM). Eur J Heart Fail 26(6):1361\u20131368","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"4157_CR28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","volume":"1","author":"YJ Shimada","year":"2013","unstructured":"Shimada YJ, Passeri JJ, Baggish AL et al (2013) Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail 1(6):480\u2013487","journal-title":"JACC Heart Fail"},{"issue":"1","key":"4157_CR29","doi-asserted-by":"publisher","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","volume":"11","author":"I Olivotto","year":"2018","unstructured":"Olivotto I, Camici PG, Merlini PA et al (2018) Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail 11(1):e004124","journal-title":"Circ Heart Fail"},{"issue":"1","key":"4157_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","volume":"11","author":"M Penicka","year":"2009","unstructured":"Penicka M, Gregor P, Kerekes R et al (2009) The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 11(1):35\u201341","journal-title":"J Mol Diagn"},{"issue":"5","key":"4157_CR31","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jchf.2014.11.011","volume":"3","author":"G Finocchiaro","year":"2015","unstructured":"Finocchiaro G, Haddad F, Knowles JW et al (2015) Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. JACC Heart Fail 3(5):408\u2013418","journal-title":"JACC Heart Fail"},{"issue":"20","key":"4157_CR32","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/heartjnl-2021-320569","volume":"108","author":"M Mapelli","year":"2022","unstructured":"Mapelli M, Romani S, Magr\u00ec D et al (2022) Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy. Heart 108(20):1629\u20131636 Published 2022 Sep 26","journal-title":"Heart"},{"issue":"4","key":"4157_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.amjcard.2006.02.057","volume":"98","author":"R Thaman","year":"2006","unstructured":"Thaman R, Esteban MT, Barnes S et al (2006) Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98(4):515\u2013519","journal-title":"Am J Cardiol"},{"issue":"8","key":"4157_CR34","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.3346\/jkms.2022.37.e62","volume":"37","author":"JW Hwang","year":"2022","unstructured":"Hwang JW, Lee SC, Kim D et al (2022) Determinants of exercise capacity in patients with hypertrophic cardiomyopathy. J Korean Med Sci 37(8):e62 Published 2022 Feb 28","journal-title":"J Korean Med Sci"},{"issue":"10","key":"4157_CR35","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/heartjnl-2022-321853","volume":"109","author":"YJ Choi","year":"2023","unstructured":"Choi YJ, Kim HK, Hwang IC et al (2023) Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction. Heart 109(10):771\u2013778","journal-title":"Heart"},{"issue":"5","key":"4157_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cardfail.2024.09.010","volume":"31","author":"AJ Sauer","year":"2025","unstructured":"Sauer AJ, Sherrod CF, Gosch KL et al (2025) The psychometric performance of the kansas city cardiomyopathy questionnaire-12 in symptomatic obstructive hypertrophic cardiomyopathy. J Card Fail 31(5):813\u2013820","journal-title":"J Card Fail"},{"issue":"1","key":"4157_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s44348-025-00052-7","volume":"33","author":"J Lim","year":"2025","unstructured":"Lim J, Kim HK (2025) Cardiac myosin inhibitors in hypertrophic cardiomyopathy. J Cardiovasc Imaging 33(1):7","journal-title":"J Cardiovasc Imaging"},{"issue":"1","key":"4157_CR38","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1038\/s41598-019-42113-0","volume":"9","author":"D Pfau","year":"2019","unstructured":"Pfau D, Thorn SL, Zhang J et al (2019) Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure. Sci Rep 9(1):5791","journal-title":"Sci Rep"},{"issue":"13","key":"4157_CR39","doi-asserted-by":"publisher","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D (2019) Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 8(13):e012272","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"4157_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10741-023-10375-6","volume":"29","author":"MS Yacoub","year":"2024","unstructured":"Yacoub MS, El-Nakhal T, Hasabo EA et al (2024) A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Heart Fail Rev 29(2):479\u2013496","journal-title":"Heart Fail Rev"},{"issue":"20","key":"4157_CR41","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390(20):1849\u20131861","journal-title":"N Engl J Med"},{"issue":"9","key":"4157_CR42","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/ejhf.3372","volume":"26","author":"A Masri","year":"2024","unstructured":"Masri A, Barriales-Villa R, Elliott P, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Heitner SB, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Saberi S, on behalf of the FOREST-HCM Investigators (2024) Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: a 36-week analysis from FOREST-HCM. Eur J Heart Fail 26(9):1993\u20131998","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"4157_CR43","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","volume":"83","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM et al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American college of cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol 83(23):2324\u20132405","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04157-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:47Z","timestamp":1789454867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04157-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4157"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04157-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable since it is a Network meta-analysis.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No participants were recruited specifically for this study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CRD420261322639.","order":3,"name":"Ethics","label":"PROSPERO Registration Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"228"}}